Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165935 | 0.84 | HDAC1 (0.63) | HDAC1JAK2LTA4HHRH3CHRM4 | |
| SCHEMBL19496612 | 0.82 | HDAC1 (0.55) | HDAC1JAK2LTA4HHRH3NMT1 | |
| SCHEMBL5952015 | 0.82 | HDAC1 (0.57) | HDAC1JAK2LTA4HHRH3NMT1 | |
| SCHEMBL5170062 | 0.81 | HRH3 (0.60) | HDAC1JAK2LTA4HHRH3 | |
| SCHEMBL5168517 | 0.80 | HDAC1 (0.62) | HDAC1JAK2LTA4HHRH3NMT1 | |
| SCHEMBL5167736 | 0.79 | HDAC1 (0.61) | HDAC1JAK2LTA4HHRH3NMT1 | |
| SCHEMBL5169012 | 0.78 | LTA4H (0.50) | HDAC1JAK2LTA4HHRH3TNKS | |
| SCHEMBL5166411 | 0.77 | GRM2 (0.56) | HDAC1JAK2LTA4HHRH3CHRM4 | |
| SCHEMBL5165601 | 0.77 | HDAC1 (0.56) | HDAC1JAK2LTA4HHRH3PARP1 | |
| SCHEMBL5164995 | 0.77 | HDAC1 (0.53) | HDAC1JAK2LTA4HHRH3TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771438-A1 | 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2006011042-A1 | 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060014733-A1 | Histamine-3 agonists and antagonists | PFIZER INC | 2006-01-19 | — | — | US | claimed |
| EP-1771438-A1 | 1-3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006011042-A1 | 1, 3 SUBSTITUTED CYCLOAMINO DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060014733-A1 | Histamine-3 agonists and antagonists | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014733-A1 | Histamine-3 agonists and antagonists | HRH3, HRH4, HRH2 | HDAC1 1532/4885JAK2 958/4885LTA4H 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.